Geron Appoints Two New Independent Board Members
March 28, 2019 08:00 ET
|
Geron Corporation
MENLO PARK, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Dawn C. Bir and Elizabeth G. O’Farrell as independent members of its Board...
Geron Corporation Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Events
March 07, 2019 16:05 ET
|
Geron Corporation
MENLO PARK, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and full year ended December 31, 2018 and recent...
Geron to Announce Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019
February 28, 2019 16:30 ET
|
Geron Corporation
MENLO PARK, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2018 financial results after the market...
Geron Announces Expansion of Leadership Team with Appointment of Chief Medical Officer
January 31, 2019 16:20 ET
|
Geron Corporation
Aleksandra Rizo, M.D., Ph.D., former clinical lead for the imetelstat program at Janssen, joins Geron as Chief Medical OfficerAdditional office to be opened in New Jersey to support expansion of...
Geron Announces New Board Leadership Structure
December 31, 2018 07:30 ET
|
Geron Corporation
CEO John A. Scarlett Appointed Chairman Karin Eastham Appointed Lead Independent Director MENLO PARK, Calif., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced...
Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy
December 03, 2018 16:22 ET
|
Geron Corporation
Data Reporting Median Overall Survival of 29.9 Months in High-Dose Arm Presented at the 60th American Society of Hematology Annual Meeting MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) --...
Geron Reports Updated Results from Phase 2 Portion of IMerge at the 60th American Society of Hematology Annual Meeting
December 03, 2018 06:00 ET
|
Geron Corporation
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that updated results from Part 1 of IMerge, the Phase 2 portion of a Phase 2/3 clinical trial...
Geron to Present at Upcoming Investor Conferences in November
November 07, 2018 16:30 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present a...
Geron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events
November 01, 2018 16:05 ET
|
Geron Corporation
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American Society of Hematology...
Geron Announces Two Oral Presentations on Imetelstat at Upcoming American Society of Hematology Annual Meeting
November 01, 2018 06:20 ET
|
Geron Corporation
Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes and IMbark Primary Analysis in Myelofibrosis to be Presented MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Geron...